MOUNTAIN VIEW, Calif. , April 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in April: H.C. Wainwright Global Life Sciences Conference Monday,

-- Peer-reviewed findings show blocking CCR2 provides rapid and sustained renal benefit in well-established models of FSGS -- -- Improvements in renal function with CCR2 inhibition associated with encouraging histological changes, including increased podocyte density -- MOUNTAIN VIEW, Calif.

-- Phase III ADVOCATE trial of avacopan in treatment of ANCA vasculitis nears 75% of patient enrollment target as European Medicine Agency continues review process of Conditional Marketing Authorization application -- -- Strengthened balance sheet with up to $100 million in new capital commitments;

MOUNTAIN VIEW, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 38 th Annual Health Care Conference on Tuesday March 13, 2018 at 10:40 a.m. ET .

MOUNTAIN VIEW, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's fourth quarter 2017 financial results will be released before market open on Friday, March 9, 2018 . ChemoCentryx executive management will host a conference call

-- CCX872 plus FOLFIRINOX resulted in overall survival of 29 percent at 18 months in all patients --  -- Clinical findings to be presented at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium -- MOUNTAIN VIEW, Calif. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.

MOUNTAIN VIEW, Calif. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced the appointment of William (Bill) Fairey as Executive Vice President and

-- ChemoCentryx to Receive $50 Million Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis -- -- Company Also Enters into $50 Million Growth Capital Financing Agreement with Hercules Capital -- MOUNTAIN

Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney Health Alliance ChemoCentryx to receive regulatory milestone payment from VFMCRP VIFOR FRESENIUS MEDICAL

MOUNTAIN VIEW, Calif. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer,